Relevant bibliographies by topics / Cell-based immunotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cell-based immunotherapy'

Author: Grafiati
Published: 7 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cell-based immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cell-based immunotherapy"

1

Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H. Kim Lyerly. "Dendritic Cell-Based Immunotherapy." International Reviews of Immunology 25, no. 5-6 (January 2006): 377–413. http://dx.doi.org/10.1080/08830180600992456.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sabado, Rachel L., Sreekumar Balan, and Nina Bhardwaj. "Dendritic cell-based immunotherapy." Cell Research 27, no. 1 (December 27, 2016): 74–95. http://dx.doi.org/10.1038/cr.2016.157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Razzak, Mina. "New cell-based immunotherapy?" Nature Reviews Urology 9, no. 3 (February 21, 2012): 122. http://dx.doi.org/10.1038/nrurol.2012.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chang, Kiyuk, Jie-Young Song, and Dae-Seog Lim. "Tolerogenic dendritic cell-based immunotherapy." Oncotarget 8, no. 53 (October 17, 2017): 90630–31. http://dx.doi.org/10.18632/oncotarget.21867.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Golán, Irene, Laura Rodríguez de la Fuente, and Jose Costoya. "NK Cell-Based Glioblastoma Immunotherapy." Cancers 10, no. 12 (December 18, 2018): 522. http://dx.doi.org/10.3390/cancers10120522.

Full text
Abstract:
Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges.
APA, Harvard, Vancouver, ISO, and other styles
6

Wennhold, Kerstin, Alexander Shimabukuro-Vornhagen, and Michael von Bergwelt-Baildon. "B Cell-Based Cancer Immunotherapy." Transfusion Medicine and Hemotherapy 46, no. 1 (2019): 36–46. http://dx.doi.org/10.1159/000496166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Urbonas, Vincas, Giedre Smailyte, Greta V. Urbonaite, Audrius Dulskas, Neringa Burokiene, and Vytautas Kasiulevicius. "Natural killer cell-based immunotherapy." Melanoma Research 29, no. 2 (April 2019): 208–11. http://dx.doi.org/10.1097/cmr.0000000000000552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kadowaki, Norimitsu, and Toshio Kitawaki. "V. Dendritic Cell-based Immunotherapy." Nihon Naika Gakkai Zasshi 108, no. 7 (July 10, 2019): 1391–96. http://dx.doi.org/10.2169/naika.108.1391.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stagg, J., and M. J. Smyth. "NK cell-based cancer immunotherapy." Drug News & Perspectives 20, no. 3 (2007): 155. http://dx.doi.org/10.1358/dnp.2007.20.3.1092096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Buckler, Lee. "Rise of Cell-Based Immunotherapy." Genetic Engineering & Biotechnology News 33, no. 5 (March 2013): 12–13. http://dx.doi.org/10.1089/gen.33.5.05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cell-based immunotherapy"

1

Cabezón, Cabello Raquel. "Tolerogenic dendritic cell-based immunotherapy in Crohn’s disease." Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/310604.

Full text
Abstract:
The quality of life of a significant proportion of IBD patients is poor as a result of persistent disease activity and repeated surgery, among others. Current treatments for Crohn’s disease are not able to neither prevent this serious impact nor improve the long term prognosis of a significant proportion of patients. Therefore, new therapeutic approaches are needed in order to modify the immune response of these patients. We hypothesize that administration of ex-vivo generated autologous tol-DCs to Crohn’s disease patients may arrest Th1 lymphocyte proliferation and therefore may restore specific tolerance against non-pathogenic antigens in the gut. The overall objective of this thesis was to generate and characterize tol-DCs for the purpose of implementing an autologous immunotherapy treatment for Crohn’s disease patients. In the first study, we described the generation of tol-DCs from healthy donors and Crohn’s disease patients by use of clinical-grade reagents in combination with dexamethasone as immunosuppressive agent and characterized their functional properties. Our main findings demonstrated that the combination of dexamethasone with a specific cytokine cocktail yields clinical-grade DCs with the following characteristics: a semi-mature phenotype, a pronounced shift towards anti-inflammatory versus inflammatory cytokine production and low T-cell stimulatory properties. This characteristic tolerogenic profile is maintained when tol-DCs are activated using heat-inactivated Gram-negative bacteria as maturative stimulus. Whole microorganisms contain multiple PAMPs capable of stimulating DCs by different pathways. Our results clearly showed a strong inhibitory effect on DC phenotype, a robust inhibition of pro-inflammatory cytokines, increased IL-10 secretion, and inhibition of T-cell proliferation and Th1 induction. Interestingly, we showed that tol-DCs have reduced immunogenic capacity in autologous, allogeneic and antigen-specific T-cell responses. We further evaluated the ability of tol-DCs to induce CD4+ T-cell hypo-responsiveness. Our results demonstrated that T-cells or antigen-specific T-cells previously cultured with tol-DCs are anergic exhibiting a reduced capacity to proliferate as well as reduced IFN-gamma secretion when rechallenged with fully competent mDCs. With regard to tol-DCs clinical application, we importantly found that their tolerogenic properties remain stable after washing out dexamethasone and subsequent restimulation with LPS, CD40L or different Gram-negative enterobacteria strains. All these properties led us to conclude that this cell product is suitable to be tested in clinical trials of immune-based diseases such as Crohn’s disease. We further identified a positive biomarker for tol-DCs, MERTK receptor is highly expressed on clinical grade dexamethasone-induced human tol-DCs and contributes in their tolerogenic properties. Our results demonstrated that MERTK expression in human DCs is regulated by glucocorticoids and described a new function of this receptor in directly regulating T-cell response. Interestingly, our findings showed that neutralization of MERTK with monoclonal antibodies in allogeneic MLR cultures leads to increased T-cell proliferation and IFN-gamma production. The direct regulation of T-cell response was confirmed by the use of recombinant MERTK-Fc protein, used to mimic MERTK on DCs. Our results remarkably showed that MERTK-Fc suppresses naïve and antigen-specific memory Tcell proliferation and activation. These findings identified a new non-cell autonomous regulatory function of MERTK expressed on DCs. Additionally, we described that this regulation is mediated by the neutralization of MERTK soluble ligand PROS1. We also found that MERTK is expressed on T-cell surface and that PROS1 drives an autocrine pro-proliferative effect on these cells. In summary, the results of this work demonstrated that MERTK on DCs regulates T-cell activation and expansion through the competition for PROS1 interaction with MERTK in the T-cells. We showed that MERTK expression in human DCs has a key role in instructing adaptive immunity and identified MERTK as a potent suppressor of T-cell response. Therefore targeting MERTK may provide an interesting approach to effectively increase or suppress tolerance for the purpose of immunotherapy.
Esta tesis doctoral estudia el proceso de generación de células dendríticas tolerogénicas en grado clínico, con el objetivo de establecer un protocolo destinado al tratamiento de la enfermedad de Crohn. El estudio realizado ha permitido la caracterización de dichas células y sus propiedades tolerogénicas, incluyendo la descripción novedosa de un marcador de células tolerogénicas y el estudio de sus propiedades funcionales relacionadas con la inducción de tolerancia.
APA, Harvard, Vancouver, ISO, and other styles
2

Vertuani, Simona. "Strategies to optimize T cell-based cancer immunotherapy /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-891-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Hung-Chang. "Human γδ T cell-based immunotherapy for breast cancer." Thesis, Cardiff University, 2015. http://orca.cf.ac.uk/86751/.

Full text
Abstract:
Scientific background. The inherent resistance of breast cancer stem cells (CSCs) to existing therapies has largely hampered effective treatments for advanced breast cancer. My research aimed at establishing novel immunotherapy approaches efficiently targeting CSCs by harnessing human γδ T cells as non-MHC-restricted killer cells and simultaneously as APCs to induce tumour-specific CD8+ T cell responses. Approach. An experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with γδ T cells and CD8+ T cells. FluM1 and CMVpp65 viral epitopes were used as surrogates for yet-to-be-discovered CSC-associated antigens. Results. Stable sublines with characteristics of CSCs and non-CSCs were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their (i) distinct expression profiles of CD24, CD44 and GD2, (ii) mesenchymal- and epitheliallike characteristics, (iii) differential growth patterns in mammosphere culture and (iv) distinct tumourigenicity, self-renewal and differentiation in NSG mice. The resistance of both CSCs and non-CSCs to γδ T cells could be overcome by inhibition of FPPS through pretreatment with zoledronate or FPPS-targeting shRNA, resulting in increased cytotoxicity and APC function of γδ T cells. CSCs presenting FluM1 or CMVpp65 exhibited stronger resistance to antigen-specific CD8+ T cells as compared to their non-CSC counterparts. Of note, pretreatment of Flu M1- or CMVpp65-presenting CSCs with γδ T cell conditioned supernatant significantly increased surface expression of MHC class I and ICAM-1 by both CSCs and non-CSCs as well as their susceptibility to CD8+ T cellmediated killing. Moreover, using the humanised anti-GD2 monoclonal antibody,Hu14.18K322A, a specific direction of γδ T cell responses against CSCs could be achieved. In addition to their direct cytotoxicity and ability to modulate the susceptibility of CSCs and non-CSCs to CD8+ T cell-mediated killing, γδ T cells concomitantly functioned as APCs to initiate de novo tumour-specific cytotoxic CD8+ T cell responses. Conclusions. My findings identify a powerful synergism between MHC-restricted and non-MHC-restricted T cells in the eradication of both CSCs and non-CSCs, thus establishing a powerful positive feedback loop for the eradication of residual cancer cells survived from killing by γδ T cells. My research suggests that novel immunotherapies may benefit from a two-pronged approach combining γδ T cell and CD8+ T cell targeting strategies that triggers effective innate-like and tumour-specific adaptive responses.
APA, Harvard, Vancouver, ISO, and other styles
4

Cheong, Siew Chiat. "Development of cancer immunotherapy based on parvoviral vectors and hybrid cell vaccination." Doctoral thesis, Universite Libre de Bruxelles, 2005. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/211033.

Full text
Abstract:
Cancer is a worldwide health problem and despite advances in traditional treatments i.e. surgery, chemotherapy and radiotherapy, the cure rate remains disappointing for some cancers. Different novel therapeutic strategies are being developed. In this thesis two nontraditional cancer therapy approaches are studied: gene therapy using viral vectors and antitumour vaccination with dendritic cell - tumour cell (DC/TC) hybrids.

We have developed a novel ELISPOT titration method for viral vectors that is based on the actual expression of the transgene in target cells. This method was developed with recombinant parvovirus MVM-IL2, but it should be adaptable for other vectors carrying expression cassettes for secreted transgene products for which antibodies are available. The ELISPOT titration method allows for faster and better quantification of transducing units present in vector stocks as opposed to titration by in situ hybridisation (annexe I). The MVMIL2 vector has shown an anti-tumour effect against melanoma in an immunocompetent mouse model (annexe IV). Previous work concerns photodynamic inactivation of adenoviral vectors for biosafety and an in vivo study in which a synergistic effect of antiangiogenesis gene therapy combined with radiotherapy could be shown (annexes V and VI).

DC/TC hybrids have been proposed as cancer vaccines for their simultaneous expression of antigen presentation machinery and tumour associated antigens. Hybrids are classically generated by polyethylene glycol (PEG) or electrofusion. These methods however require special skills and equipment and cause rather high cell lethality. Fusion via the expression of viral fusogenic membrane glycoproteins (FMG), such as the vesicular stomatitis virus-G (VSV-G) (annexe III) or the Gibbon ape Leukemia Virus (GaLV) FMG, have recently been described. We have mainly focussed on the latter. Transduction of cells with GaLV-FMG proved to be a limiting step for an efficient generation of hybrids. On the other hand, constitutive expression of GaLV-FMG leads to lethal syncytia formation in human cells. Therefore we developed a novel fusion strategy for the generation of DC/TC cell hybrids that involves the use of a non-human fusogenic cell line that constitutively expresses the GaLV-FMG. With this method we were able to generate reproducible yields of DC/TC triparental hybrids. The formation of tri-parental hybrids via the fusogenic cell line is an interesting alternative to existing DC/TC fusion methods because of its simplicity and its flexibility in the choice of fusion partners, i.e. autologous or allogeneic DCs and tumour cells.

Moreover, the tri-parent hybrid system offers the possibility to further enhance the immune response by the addition of transgenes that code for immuno-modulating factors to the fusogenic cell line (annexe II).
Doctorat en sciences biomédicales
info:eu-repo/semantics/nonPublished

APA, Harvard, Vancouver, ISO, and other styles
5

Klammer, Matthias. "Development of a dendritic cell-based vaccine for the immunotherapy of Acute Myeloid Leukaemia." Thesis, University of Edinburgh, 2008. http://hdl.handle.net/1842/29202.

Full text
Abstract:
22 patients with de novo or relapsed Acute Myeloid Leukaemia (AML) were recruited into a Phase I/II clinical trial aimed at vaccinating with autologous dendritic like leukaemia cells once in complete remission. At trial entry leukaemia cells were harvested and tested for their permissiveness to cytokine-induced dendritic cell differentiation. Study patients were then treated with induction chemotherapy. Five patients achieved both complete remission and had leukaemia cells that were permissive to differentiation, and were therefore eligible to proceed to vaccination. Four escalating doses of dendritic like leukaemia cells were administered weekly by subcutaneous injection. An increase in anti-leukaemic T cell responses was demonstrated in four patients. Vaccination was generally well tolerated. Two patients relapsed during or shortly after the vaccination schedule. In the remaining three patients, one relapsed at 12 months with two in continued remission more than 12 months post vaccination. In a parallel investigation, the potential of Tumour Cell / Dendritic Cell Fusion Hybrids to generate in vitro anti-leukaemic T-cell responses following co-culture with autologous remission lymphocytes was assessed in six patients with AML. Comparison was made to anti-leukaemic responses induced by mature dendritic cells (mDC) co-cultured with autologous, irradiated myeloid blasts. Fusion Hybrids induced anti-leukaemic T-cell responses in three out of six patients. Tumour pulsed mature dendritic cells induced T-cellular responses in two other patients. Only one of six patient’s remission lymphocytes failed to develop leukaemia directed immune responses following stimulation with either construct. Anti-proliferative properties of Fusion Hybrids against allergenic lymphocytes were observed in mixed lymphocyte-leukaemia reactions (MLLR) and were found not to be specific to the cell fusion partners and do not prevent the ability of AML-mDC heterokaryons to induce autologous anti-leukaemic cytotoxicity. In conclusion, Tumour Cell / Dendritic Cell Fusion Hybrids hold promise as a cellular vaccine for Acute Myeloid Leukaemia.
APA, Harvard, Vancouver, ISO, and other styles
6

Costigliola, Emanuele. "Development of herpes simplex virus 1 vectors for dendritic cell based immunotherapy of malaria." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1444585/.

Full text
Abstract:
Herpes simplex virus 1 (HSV-1) naturally infects dendritic cells but this prevents the cell from undergoing maturation. Removal of the virus host shutoff protein (vhs) has been shown to improve the ability of both human dendritic cells and mouse bone marrow dendritic cells to mature following virus infection. An HSV-1 vhs" backbone was further modified by deletion of the ICP47 gene and mutation of the VP 16 gene resulting in a vector that does not interfere at all with the ability of mouse dendritic cells to mature. This virus therefore, provided a good candidate for use as vector for antigen delivery in immunotherapy. A recombinant vhs"ICP47"VP16" virus expressing the full length influenza nucleoprotein (NP) was constructed and used to determine the ability of this virus to induce immune responses upon immunisation with virus alone or upon immunisation with infected DCs. Both cellular and humoral responses were investigated and a CD8+ CTL response to both the NP gene and to the virus was obtained after different immunisation regimes confirming the potential of the virus to be used for immunotherapy. In the attempt to further improve the vector, mGMCSF was added to the viral constructs and viruses expressing both mGMCSF and NP or full length Plasmodium yoelii sporozoite surface protein 2 (PySSP2) or circumsporozoite protein (PyCS) were constructed. The effect of co-expressing mGMCSF from the virus was investigated. A convincing CD8+ CTL response was obtained against - the antigen upon direct virus injection though co-expression of mGMCSF did not seem to confer a significant advantage. Overall an HSV-1 vector has been developed and optimised for the infection of dendritic cells and then successfully used for induction of specific CTL and antibody response to full length NP, PySSP or PyCS.
APA, Harvard, Vancouver, ISO, and other styles
7

Wahid, S. Fadilah Binti Abdul. "Development of functional human dendritic cell subsets in vitro and in vivo in hu/NOD/SCID chimeric mice : important implications in dentritic cell-based immunotherapy /." [St. Lucia, Qld.], 2005. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe19089.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

De, la Pena H. "Development of a novel nanotechnology based artificial antigen presenting cell system for adoptive and active immunotherapy." Thesis, University College London (University of London), 2007. http://discovery.ucl.ac.uk/1446304/.

Full text
Abstract:
T cells are one of the most pivotal cell types in the human adaptive immune system. They have the capacity to eradicate primary, metastatic, relapsed tumours and can ameliorate otherwise fatal viral infections. Not surprisingly therefore, the activation and expansion of T cells has become one of the main focuses for immunotherapy and immune gene therapy. However one of the problems of T cell mediated immunotherapy in terms of delivering significant clinical impact to patients, is the expansion of high numbers of functional antigen specific effector T cells. The current approaches for expanding T cells have a number of drawbacks in terms of timing, reproducibility and reliability. Many if not all the currently available systems rely on ex vivo cell manipulation, which concordantly leads to short T cell survival in vivo after infusion. In vivo artificial expansion systems would clearly circumvent this problem. Nevertheless active immunotherapy is not always the solution since sometimes in some patients, the T cells that could be potentially in- vivo expanded no longer exist because they have been deleted, killed or anergised. Therefore a flexible system should be constructed in order to performed both adoptive and/or active immunotherapy depending on the patients requirements. Currently there is no comprehensive artificial Antigen Presenting Cell system (aAPC) for both effective ex vivo and in vivo antigen specific T cell expansion. Therefore in order to address this we have constructed a novel artificial nano-sized super para magnetic antigen presenting cell system (aAPC) capable of priming and expanding antigen specific T cells ex vivo and in vivo. As defined by the NIH, nanotechnology uses nanoscale injectable, targeted and traceable devices capable of important immunological/clinical functions. This nano-system was constructed using the latest generation of immuno liposomes, approved for in vivo human use since they are non-toxic, biodegradable, avoid rapid recognition by the reticulo endothelial system, are safe in terms of size being 50 times smaller than average cells at lOOnm, have good stability and favourable pharmacokinetic behaviour for effective in vivo trafficking. We have coated these liposomes with an optimised number of MHC Class I / peptide complexes and a specific selected range of adhesion (anti LFA-1), early activation (anti CD28 and anti CD27), late activation (4-IBB) and survival receptors (anti CD40L) in the form of Fab antibody regions or monoclonal antibodies. We have made these immuno liposomes traceable since they carry fluorescent lipids and iron oxide super para magnetic nano particles or spios of 13nm size, which make them traceable in vivo using fluorescence and/or by Magnetic Resonance Imaging (MRI). The super para magnetic liposomes are also able to facilitate their own focusing to specific organs, tumour sites or body areas by applying external magnetic attraction. Production of this nano immune liposome system in a ready to use form is achievable in less than 48 hrs and viable for at least 7 days. After ex vivo stimulation with this artificial nano system using CMV pp65 as a model antigen, we have established successful expansions with high T cell numbers (55 to 200 fold) in CMV positive individuals, which are superior when compared with other systems such as peptide pulsed DCs, which are one of the standard methods currently used, coated Daudi cells, magnetic commercial beads and modified tetramers. The T cells are fully functional in terms of degranulation and production of cytokines when specifically challenged. They express predominantly effector-memory and memory phenotypes. We have demonstrated by double fluorescent staining that these liposomes activate T cells directly in an antigen specific fashion and also semi-directly by being incorporated on the surface of the natural APCs in a similar manner as exosomes. When tested in naive individuals, this nano system was also capable of accomplishing initial low levels of T cell priming without help of any adjuvants. In conclusion, we have generated an efficient artificial APC, which embodies a powerful, controllable and superior approach with enormous potential for cancer nanotechnology and T cell immunotherapy for use either in vivo or in vitro.
APA, Harvard, Vancouver, ISO, and other styles
9

BOLLI, ELISABETTA. "Dendritic-Cell (DC)-Based Immunotherapy: Tumor Endothelial Marker 8 (TEM8) Gene Expression of DC Vaccines Correlates with Clinical Outcome." Doctoral thesis, Università degli Studi di Camerino, 2008. http://hdl.handle.net/11581/401881.

Full text
Abstract:
ABSTRACT Previous studies have shown that tumor-endothelial markers (TEMs) are upregulated in immunosuppressive, pro-angiogenic dendritic cells (DCs) found in tumor microenvironments. We reported that pro-angiogenic monocyte-derived DCs (Mo-DCs), utilized for therapeutic vaccination of cancer patients upon maturation, markedly differ in their ability to up-regulate tumor-endothelial marker 8 (TEM8) gene expression. A DC vaccination trial of 17 advanced cancer patients (13 melanoma and 4 renal cell carcinoma), carried out at the Cancer Institute of Romagna (I.R.S.T.) in Meldola, highlighted a significant correlation between delayed-type hypersensitivity test (DTH) and overall survival (OS). In the study, relative TEM8 mRNA and protein expression levels (mature (m) vs. immature (i) DCs), in DCs obtained for therapeutic vaccines were evaluated by quantitative real-time RT-PCR and cytofluorimetric analysis, respectively. mDCs from six healthy donors were included for comparison purposes. Eight non-progressing patients, all DTH-positive, had a mean fold increase (mfi) of 1.97 in TEM8 expression. Similarly, a TEM8 mRNA mfi = 2.7 was found in healthy donor mDCs. Conversely, mDCs from nine progressing patients, all but one with negative DTH, had a TEM8 mRNA mfi of 12.88. Thus, mDC TEM8 expression levels would seem to identify (p = 0.0018) patients who could benefit from DC therapeutic vaccination.
APA, Harvard, Vancouver, ISO, and other styles
10

PIZZITOLA, IRENE. "Chimeric antigen receptor: a cell therapy based approach for the treatment of acute myeloid leukemia." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2013. http://hdl.handle.net/10281/40113.

Full text
Abstract:
Despite the progress in the treatment of acute myeloid leukemia (AML) achieved in the last decades, a significant number of patients are still refractory to or relapse after standard cures. Hence, to improve cure rates of AML, it is crucial to develop novel therapeutic strategies. Immunotherapy with T cells genetically modified to express chimeric antigen receptors (CARs) represent a valid option in this sense. CARs are artificial molecules constituted by an extracellular-antigen-binding domain derived from a monoclonal antibody and an intracellular-signalling region that is immediately triggered after antigen recognition. Therefore, CARs combine the antigen binding properties of mononoclonal antibodies to T cell mediated effector functions, including the killing mechanism -that might be active against antibody resistant targets-, cytokine secretion- that might boost the anti-tumoral immune response- and capacity to efficiently home and infiltrate tumor sites. Different CARs have been generated so far, against a wide range of surface molecules expressed by many tumors and, currently, several phase I clinical trials are undergoing and the results obtained so far are very encouraging. The CARs approach can be employed to selectively target AML cells due to the overexpression of myeloid antigens, like CD33 and CD123. We recently demonstrated that expression of CD33-specific CARs in a population of ex-vivo activated T cells, called “cytokine induced killer” (CIK) cells, confers them potent in vitro anti-leukemic functions. However, since CD33 antigen is also expressed on normal haematopoietic stem/progenitors cells (HSPCs) resulting in a potential severe impairment of normal myelopoiesis, CD123 has recently been proposed as a new potential attractive molecule based on its differential expression pattern, being widely overexpressed by AML population and at the same time less expressed on HSPCs. In order to improve the safety profile against these cells we develop and test a novel CAR specific for the CD123 antigens. Here we describe the in vitro and the in vivo efficacy and the safety of this approach based on CIK cells genetically modified to express CAR molecules specific for the CD33 or CD123 antigen. The development and the optimization of the proposed strategy could be a good potential therapeutic tool in the context of minimal residual disease in high-risk transplanted AML patients. Moreover, CAR approach could be potentially used to treat patients resistant to conventional chemotherapeutic approaches or for whom high dose chemotherapy treatment could not be proposed.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cell-based immunotherapy"

1

García-Olmo, Damián. Cell therapy. Edited by García-Verdugo José Manuel. New York: McGraw-Hill Interamerica, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kang, Chʻang-yul. Pairŏsŭ pektʻŏ ro hyŏngjil toiptoen hangwŏn chesi sepʻo ŭi myŏnyŏk chʻiryoje yuhyosŏng pʻyŏngka mit sihŏmpŏp yŏnʼgu =: Development and estimation of immunotherapeutic cell-based vaccine approaches using antigen presenting cells transduced with viral vector. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cell-Based Cancer Immunotherapy. Elsevier Science & Technology Books, 2024.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Borrego, Francisco, Susana Larrucea, Rafael Solana, and Raquel Tarazona, eds. NK Cell-Based Cancer Immunotherapy. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-934-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Santich, Brian H., Nai-Kong Cheung, and Christian Klein, eds. Bispecific Antibodies for T-Cell Based Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-415-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dal Col, Jessica, Alejandro López-Soto, and Riccardo Dolcetti, eds. Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-726-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology Books, 2024.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cell-based immunotherapy"

1

Motohashi, Shinichiro. "NKT Cell-Based Immunotherapy." In Immunotherapy of Cancer, 75–86. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55031-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Berger, T. G., and E. S. Schultz. "Dendritic Cell-Based Immunotherapy." In Current Topics in Microbiology and Immunology, 163–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-662-06508-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Okamoto, Masato. "Dendritic Cell-Based Vaccine for Cancer." In Immunotherapy of Cancer, 197–220. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55031-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Matsushita, Hirokazu, and Kazuhiro Kakimi. "γδ T Cell-Based Cancer Immunotherapy." In Immunotherapy of Cancer, 99–119. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55031-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Westdorp, H., K. F. Bol, M. Coşkuntürk, G. Schreibelt, I. J. M. de Vries, and C. G. Figdor. "Dendritic Cell-Based Cancer Vaccines." In Cancer Immunotherapy Meets Oncology, 69–87. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-05104-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bol, K. F., G. Schreibelt, E. H. J. G. Aarntzen, I. J. M. de Vries, and C. G. Figdor. "Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts." In Cancer Immunotherapy, 71–108. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-4732-0_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Foltz, Jennifer A., Jeffrey S. Miller, and Dean A. Lee. "Natural Killer Cell-Based Immunotherapy." In Immunotherapy in Translational Cancer Research, 215–27. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118684535.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shojaeefar, Ehsan, and Nima Rezaei. "Dendritic Cell-Based Cancer Immunotherapy." In Handbook of Cancer and Immunology, 1–28. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-80962-1_193-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Deschoolmeester, Vanessa, David Kerr, Patrick Pauwels, and Jan B. Vermorken. "Cell Based Therapy: Modified Cancer Cells." In Immunotherapy for Gastrointestinal Cancer, 23–46. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43063-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mirza, Noweeda, and Dmitry Gabrilovich. "Different Approaches to Dendritic Cell-Based Cancer Immunotherapy." In Immunotherapy of Cancer, 127–38. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59745-011-1:127.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cell-based immunotherapy"

1

Thielemans, Kris. "Abstract B36: mRNA and dendritic cell based immunotherapy." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-b36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tent, Michiel. "Allogenic T-cell-based immunotherapy for PML in development." In AAN 2023, edited by Prof Hans-Peter Hartung. Baarn, the Netherlands: Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/6fcade78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hoke, Austin T., Yoko Takahashi, Michelle R. Padget, Moran Amit, Jared Burks, Javier Gomez, Diana Bell, et al. "NK Cell-Based Immunotherapy Approaches to Sinonasal Undifferentiated Carcinoma." In 32nd Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2023. http://dx.doi.org/10.1055/s-0043-1762160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Hyunjoon, Peter Larson, Tamara A. Kucaba, Katherine A. Murphy, David M. Ferguson, Thomas S. Griffith, and Jayanth Panyam. "Abstract 718: Nanoparticle-based tumor cell lysate vaccine for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-718.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Funk, MA, PM Brunner, C. Jonak, M. Deseke, I. Prinz, J. Leitner, J. Stöckl, and P. Steinberger. "P09.09 A CAR-T cell-based approach for the treatment of malignant T cell diseases." In iTOC9 – 9th Immunotherapy of Cancer Conference, September 22–24, 2022 – Munich, Germany. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-itoc9.65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ascic, Ervin, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, et al. "1281 A cancer immunotherapy modality based on dendritic cell reprogramming in vivo." In SITC 39th Annual Meeting (SITC 2024) Abstracts, A1436. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.1281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Beyrend, G. "PO-362 Rational designing combinatorial T-cell based immunotherapy by high-dimensional profiling." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.874.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Beyrend, G. "PO-375 Rational designing combinatorial T-cell based immunotherapy by high-dimensional profiling." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.886.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Korbelik, Mladen, and Jinghai Sun. "Cancer treatment by photodynamic therapy combined with NK-cell-line-based adoptive immunotherapy." In BiOS '98 International Biomedical Optics Symposium, edited by Steven L. Jacques. SPIE, 1998. http://dx.doi.org/10.1117/12.308148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kumai, Takumi, Ryusuke Hayashi, Tatsuya Hayashi, Hiroya Kobayashi, and Yasuaki Harabuchi. "Abstract 6622: The identification of extranodal NK/T cell lymphoma-associated antigen for helper T cell-based immunotherapy." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6622.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cell-based immunotherapy"

1

Mathis, James M. Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2007. http://dx.doi.org/10.21236/ada491946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mathis, James M. Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2008. http://dx.doi.org/10.21236/ada518244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mathis, James M. Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2005. http://dx.doi.org/10.21236/ada462730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baar, Joseph. Dendritic Cell-Based Immunotherapy of Breast Cancer: Modulation by CpG. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada431640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Baar, Joseph. Dendritic Cell-Based Immunotherapy of Breast Cancer: Modulation by CpG DNA. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada412155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rausch, Matthew. Enhancement of Dendritic Cell-Based Immunotherapy Using a Small Molecule TGF-beta Receptor Type I Kinase Inhibitor. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada487435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ouyang, Zhiqiang, Qian Li, Guangrong Zheng, Tengfei Ke, Jun Yang, and Chengde Liao. Radiomics for predicting tumor microenvironment phenotypes in non-small cell lung cance: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0060.

Full text
Abstract:
Review question / Objective: Tumor microenvironment (TIME) phenotype is an important factor to affect the response and prognosis of immunotherapy in non-small cell lung cancer (NSCLC). Recently, accumulating studies have noninvasivly perdited the TIME phenotypes of NSCLC by using CT or PET/CT based radiomics. We will conduct this study by means of meta-analysis to eveluate the power and value of CT or PET/CT based radiomics for predicting TIME phenotypes in NSCLC patients. Condition being studied: At present, several recent prospective or retrospective cohort studies and randomized controlled studies have confirmed that CT or PET/CT-based radiomics were the potential tools to predict TIME phenotypes in NSCLC. However, this conclusion is controversial because of the difference of prediction profermance of different studies. The published and unpublished investigations will be included in this study. We will comprehensively evaluate the heterogeneity of these investigations, and the power and value of radiomics for predicting TIME phenotypes.
APA, Harvard, Vancouver, ISO, and other styles
8

Wangi, Yuanyuan, Lin Zhang, Yu Liu, Yu Liu, Hui Yu, Anlin Li, Tingting Liu, et al. The ICI-based therapy landscape in resectable non-small cell lung cancer: a comparative analysis of treatment efficacy and safety between neo-adjuvant, adjuvant and perioperative immunotherapy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2023. http://dx.doi.org/10.37766/inplasy2023.10.0084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Parikh, Romil R., Alexander Troester, Bronwyn Southwell, Elizabeth Ester, Shahnaz Sultan, Amy M. Claussen, Edward Greeno, et al. Treatment of Stages I–III Squamous Cell Anal Cancer: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), August 2024. http://dx.doi.org/10.23970/ahrqepccer273.

Full text
Abstract:
Objectives. To evaluate the comparative effectiveness and harms of initial treatment and posttreatment surveillance strategies for stages I–III squamous cell anal cancer. Data sources. MEDLINE®, Embase®, Cochrane Register of Controlled Trials, and ClinicalTrials.gov from January 2000 through March 2024; reference lists of systematic reviews and included studies; and a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) and nonrandomized studies of interventions (NRSIs) comparing strategies for chemotherapy, radiation therapy (RT), and surgery; modalities, doses, volumes, and fractionation schema for RT; dose de-escalation or escalation in chemoradiation (CRT); immunotherapy; and posttreatment surveillance. We evaluated risk of bias (RoB) using the RoB2 tool for RCTs and the ROBINS-I tool for NRSIs and strength of evidence (SOE) using Agency for Healthcare Research and Quality Evidence-based Practice Center Program methods for prespecified outcomes (PROSPERO registration number CRD42023456886). Results. We included 33 articles from 8 RCTs (6 with low to moderate RoB and 2 with high RoB) and 20 NRSIs (all with serious to critical RoB). Compared with RT alone, doublet CRT with 5-fluorouracil (5FU) plus mitomycin C (MMC) showed lower locoregional failure rate (LRF) and greater disease-specific and colostomy-free survival (CFS) (moderate to low SOE), greater hematologic toxicity (low SOE), greater overall acute harms (moderate SOE), and no difference in late harms (low SOE). Doublet CRT with 5FU plus MMC showed lower LRF (low SOE) and greater CFS and disease-free survival (DFS) (low SOE) than CRT with 5FU, and evidence was insufficient to compare harms. Compared with CRT with 5FU plus MMC, CRT with 5FU plus cisplatin did not improve several effectiveness outcomes up to 5 years, or overall acute or late harms (moderate to low SOE), showed lower hematologic toxicity (moderate SOE), and had conflicting, insufficient evidence for CFS. Triplet CRT with paclitaxel plus capecitabine plus MMC showed greater CFS, DFS, overall survival, and overall acute harms than doublet CRT with capecitabine plus MMC (low SOE). Remaining comparisons had insufficient evidence. Patients with older age, immunocompromised status, or minoritized racial/ethnic identities were underrepresented in included studies. Conclusions. Doublet CRT is likely more effective but may have greater hematologic toxicity compared with RT alone or CRT with 5FU. Adding paclitaxel to doublet CRT may increase treatment efficacy and toxicity. Evidence is insufficient for optimal posttreatment surveillance strategies, quality of life, and other patient-reported outcomes. Future RCTs should increase inclusion of historically underrepresented patients, and future real-world evidence generation must prioritize methodological rigor.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cell-based immunotherapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography